Overview

A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to determine the rate and extent of absorption of one or more modified release formulations of amphetamine (HLD100) in both adolescents and children with ADHD.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Ironshore Pharmaceuticals and Development, Inc

Treatments:

Amphetamine